EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rare antigen‐negative red blood cells from pluripotent stem cells for precision transfusion medicine

Naomi Gunawardena, Hyun Hyung An, Randall W Veliquette iD, Edmund Carvalho, Sambit Dalui, Kaoru Takasaki iD, Eric Wafula, Deborah L French, Giulia Pavani, Stella T Chou

Transfusion · 2026-07 · 66 (7) · 1257-1264

DOI: 10.1111/trf.70243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, online erschienen am 24.04.2026. Verfasst von Naomi Gunawardena und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Erythrocytes, Induced Pluripotent Stem Cells, Transfusion Medicine, Pluripotent Stem Cells. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Distinguished Chair in Pediatrics, NHLBI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Blood bank identification of antibodies against high‐prevalence antigens remains a challenge due to the scarcity of antigen‐negative reagent red cells sourced from blood donors. The MAM antigen, encoded by EMP3 , is one such antigen associated with red cell alloimmunization and hemolytic disease of the fetus and newborn. Study Design and Methods We used CRISPR‐Cas9 gene editing to generate an EMP3 knockout (EMP3KO) induced pluripotent stem cell (iPSC) line from a type O, Rh null parent line, enabling production of rare MAM‐negative red blood cells. Since a prior study suggested that loss of EMP3 may enhance erythroid proliferation, we hypothesized that EMP3KO could both yield a rare reagent cell and potentially improve erythroid expansion to support scalable production. Transcriptomic analysis allowed us to further investigate the effect of EMP3 loss in late erythroblasts.

Results

EMP3KO cells differentiated efficiently into erythroid cells, showing >95% CD235/CD71 co‐expression and orthochromatic erythroblast morphology. Compared to unedited cells, no proliferative advantage was observed, contrasting with prior non‐isogenic cell models. Agglutination assays confirmed complete loss of MAM antigen and demonstrated the diagnostic utility for identifying MAM antibodies. Transcriptomic profiling of EMP3KO erythroblasts revealed expression of key erythroid genes, as well as regulators of proliferation and heme metabolism, was comparable to the parent line.

Discussion

This study demonstrates that iPSC technology combined with gene editing can generate rare antigen‐negative RBCs for immunohematology applications. Beyond MAM, this platform offers a strategy to create additional rare RBC phenotypes, advancing precision transfusion medicine and improving antibody identification against high‐prevalence antigens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErythrocytesInduced Pluripotent Stem CellsTransfusion MedicinePluripotent Stem CellsHumansErythroblasts

Stichwörter der Autor:innen

MAM antigenalloimmunizationinduced pluripotent stem cellsrare red blood cells

Autor:innen und Institutionen

  • Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Department of Cell and Molecular Biology, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Immunohematology and Genomics Laboratory, New York Blood Center Enterprises, Rye, New York, USA.
  • Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Randall W Veliquette, Kaoru Takasaki

Förderung

  • Distinguished Chair in Pediatrics
  • NHLBI NIH HHS
  • NIH HHS
  • Children's Hospital of Philadelphia Breakthrough Funds
  • Mizuno Funds
  • National Institutes of Health
  • Children's Hospital of Philadelphia

Zitieren

APA

Gunawardena, N., An, H. H., Veliquette, R. W., Carvalho, E., Dalui, S., Takasaki, K., Wafula, E., French, D. L., Pavani, G., & Chou, S. T. (2026). Rare antigen‐negative red blood cells from pluripotent stem cells for precision transfusion medicine. Transfusion, 66(7), 1257-1264. https://doi.org/10.1111/trf.70243

Vancouver

Gunawardena N, An HH, Veliquette RW, Carvalho E, Dalui S, Takasaki K, et al. Rare antigen‐negative red blood cells from pluripotent stem cells for precision transfusion medicine. Transfusion. 2026;66(7):1257-1264. doi:10.1111/trf.70243

BibTeX
@article{Gunawardena2026,
  author = {Gunawardena, Naomi and An, Hyun Hyung and Veliquette, Randall W and Carvalho, Edmund and Dalui, Sambit and Takasaki, Kaoru and Wafula, Eric and French, Deborah L and Pavani, Giulia and Chou, Stella T},
  title = {Rare antigen‐negative red blood cells from pluripotent stem cells for precision transfusion medicine},
  journal = {Transfusion},
  year = {2026},
  volume = {66},
  number = {7},
  pages = {1257--1264},
  doi = {10.1111/trf.70243}
}
Kostenlos starten →